lactic acid has been researched along with Coronary Restenosis in 30 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The DESolve system, designed to provide vessel support and neointimal suppression, combines a poly-l-lactic acid-based scaffold with the antiproliferative myolimus." | 5.19 | A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. ( Abizaid, A; Abizaid, AS; Bhat, V; Chamie, D; Costa, JR; Costa, R; Morrison, L; Ormiston, JA; Pinto, I; Sanidas, E; Stewart, J; Toyloy, S; Verheye, S; Webster, M; Yan, J, 2014) |
| "PTCA-NC followed by local infusion of sirolimus nanoparticles was safe and efficacious to reduce neointima in this model, and this strategy may be a promising treatment for BMS ISR." | 3.79 | Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis. ( Attizzani, G; Balvedi, JA; Centeno, PR; Kosachenco, BG; Matte, BS; Nascimento, L; Raudales, JC; Yamamoto, GI; Zago, AC; Zago, AJ, 2013) |
| " The primary endpoint was a composite of major adverse cardiac events (MACE) at 180+/-14 days and expected to be below 20%." | 2.74 | The ProLimus trial: a prospective, non-randomised, multicentre trial to evaluate the safety and clinical performance of the pimecrolimus eluting stent system (ProGenic). ( Agostoni, P; Birkemeyer, R; Grube, E; Haine, S; Haude, M; Jung, W; Müller, R; Sarno, G; van Langenhove, G; Verheye, S; Vrints, C; Wijns, W; Willems, T, 2009) |
| "Montelukast (MK) is a selective cysLT1 receptor antagonist, with anti-inflammatory and anti-proliferative properties, which has been used for treatment of various diseases." | 1.43 | Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis. ( Mhaisalkar, PS; Prabhakaran, MP; Ramakrishna, S; Varshosaz, J; Zamani, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 15 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vergnol, G | 1 |
| Renard, E | 1 |
| Haroun, F | 1 |
| Guerin, P | 1 |
| Seron, A | 1 |
| Bureau, C | 1 |
| Loirand, G | 1 |
| Langlois, V | 1 |
| Oh, B | 1 |
| Lee, CH | 1 |
| Verheye, S | 2 |
| Ormiston, JA | 1 |
| Stewart, J | 1 |
| Webster, M | 1 |
| Sanidas, E | 1 |
| Costa, R | 1 |
| Costa, JR | 1 |
| Chamie, D | 1 |
| Abizaid, AS | 1 |
| Pinto, I | 1 |
| Morrison, L | 1 |
| Toyloy, S | 1 |
| Bhat, V | 1 |
| Yan, J | 1 |
| Abizaid, A | 1 |
| Palumbo, FS | 1 |
| Rigogliuso, S | 1 |
| Ghersi, G | 1 |
| Pitarresi, G | 1 |
| Fiorica, C | 1 |
| Calogero, F | 1 |
| Di Stefano, M | 1 |
| Giammona, G | 1 |
| Xiao, J | 1 |
| Feng, G | 1 |
| Kang, G | 1 |
| Lan, Z | 1 |
| Liao, T | 1 |
| Kislauskis, E | 1 |
| Chen, J | 1 |
| Xia, J | 1 |
| Wang, Z | 2 |
| Huo, Z | 1 |
| Wang, Q | 1 |
| Xi, T | 1 |
| McCarthy, S | 2 |
| Jiang, X | 1 |
| Wu, T | 2 |
| Laham, R | 2 |
| Vannozzi, L | 1 |
| Ricotti, L | 1 |
| Filippeschi, C | 1 |
| Sartini, S | 1 |
| Coviello, V | 1 |
| Piazza, V | 1 |
| Pingue, P | 1 |
| La Motta, C | 1 |
| Dario, P | 1 |
| Menciassi, A | 1 |
| Zamani, M | 1 |
| Prabhakaran, MP | 1 |
| Varshosaz, J | 2 |
| Mhaisalkar, PS | 1 |
| Ramakrishna, S | 1 |
| Han, Y | 1 |
| Jing, Q | 1 |
| Chen, X | 1 |
| Wang, S | 1 |
| Ma, Y | 1 |
| Liu, H | 1 |
| Luan, B | 1 |
| Wang, G | 2 |
| Li, Y | 1 |
| Wang, D | 1 |
| Xu, B | 1 |
| Gao, R | 1 |
| Ren, L | 2 |
| Wang, J | 4 |
| Tang, J | 2 |
| Pan, C | 2 |
| Huang, N | 4 |
| Soheili, M | 1 |
| Nakano, K | 1 |
| Egashira, K | 2 |
| Masuda, S | 1 |
| Funakoshi, K | 2 |
| Zhao, G | 1 |
| Kimura, S | 1 |
| Matoba, T | 1 |
| Sueishi, K | 1 |
| Endo, Y | 1 |
| Kawashima, Y | 1 |
| Hara, K | 1 |
| Tsujimoto, H | 1 |
| Tominaga, R | 1 |
| Sunagawa, K | 1 |
| Sarno, G | 1 |
| Müller, R | 1 |
| Birkemeyer, R | 1 |
| Vrints, C | 1 |
| Jung, W | 1 |
| Agostoni, P | 1 |
| van Langenhove, G | 1 |
| Haine, S | 1 |
| Willems, T | 1 |
| Haude, M | 1 |
| Grube, E | 3 |
| Wijns, W | 2 |
| Zou, W | 1 |
| Cao, G | 1 |
| Xi, Y | 1 |
| Zhang, N | 1 |
| Rodriguez, AE | 1 |
| Vigo, CF | 1 |
| Delacasa, A | 1 |
| Mieres, J | 1 |
| Fernandez-Pereira, C | 1 |
| Bernardi, V | 1 |
| Bettinoti, M | 1 |
| Rodriguez-Granillo, AM | 1 |
| Rodriguez-Granillo, G | 1 |
| Santaera, O | 1 |
| Curotto, V | 1 |
| Rubilar, B | 1 |
| Tronge, J | 1 |
| Palacios, IF | 1 |
| Antoniucci, D | 1 |
| Danzi, GB | 1 |
| Chevalier, B | 1 |
| Ostojic, M | 1 |
| Hamilos, M | 1 |
| Ma, X | 1 |
| Oyamada, S | 1 |
| Gao, F | 1 |
| Robich, MP | 1 |
| Wu, H | 1 |
| Wang, X | 1 |
| Buchholz, B | 1 |
| Gu, Z | 1 |
| Bianchi, CF | 1 |
| Sellke, FW | 1 |
| Indolfi, L | 1 |
| Causa, F | 1 |
| Giovino, C | 1 |
| Ungaro, F | 1 |
| Quaglia, F | 1 |
| Netti, PA | 1 |
| Kadota, K | 1 |
| Muramatsu, T | 1 |
| Iwabuchi, M | 1 |
| Saito, S | 1 |
| Hayashi, Y | 1 |
| Ikari, Y | 1 |
| Nanto, S | 1 |
| Fujii, K | 1 |
| Inoue, N | 1 |
| Namiki, A | 1 |
| Kimura, T | 1 |
| Mitsudo, K | 1 |
| Koppara, T | 1 |
| Joner, M | 1 |
| Bayer, G | 1 |
| Steigerwald, K | 1 |
| Diener, T | 1 |
| Wittchow, E | 1 |
| Zago, AC | 1 |
| Raudales, JC | 1 |
| Attizzani, G | 1 |
| Matte, BS | 1 |
| Yamamoto, GI | 1 |
| Balvedi, JA | 1 |
| Nascimento, L | 1 |
| Kosachenco, BG | 1 |
| Centeno, PR | 1 |
| Zago, AJ | 1 |
| Sonoda, S | 1 |
| Ikeno, F | 1 |
| Honda, Y | 1 |
| Kar, S | 1 |
| Chan, C | 1 |
| Gerckens, U | 1 |
| Lansky, AJ | 1 |
| Fitzgerald, PJ | 1 |
| Yin, T | 1 |
| Bhargava, B | 1 |
| Reddy, NK | 1 |
| Karthikeyan, G | 1 |
| Raju, R | 1 |
| Mishra, S | 1 |
| Singh, S | 1 |
| Waksman, R | 1 |
| Virmani, R | 1 |
| Somaraju, B | 1 |
| Zweers, ML | 1 |
| Engbers, GH | 1 |
| Grijpma, DW | 1 |
| Feijen, J | 1 |
| Buellesfeld, L | 1 |
| Pan, CJ | 2 |
| Shao, ZY | 2 |
| Tang, JJ | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267] | 100 participants (Anticipated) | Interventional | 2015-05-31 | Completed | |||
| Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease[NCT01373632] | Phase 4 | 570 participants (Anticipated) | Interventional | 2011-06-30 | Recruiting | ||
| Comparison Among a Paclitaxel Eluting Stent With Biodegradable Polymer Versus an Uncoated Bare Metal Stent. A Prospective, Multicentric and Randomized Study.(EUCATAX Trial)[NCT00825279] | Phase 4 | 300 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Percutaneous Complete Revascularization Strategies Using Sirolimus Eluting Biodegradable Polymer Coated Stents in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease[NCT03621501] | 1,525 participants (Actual) | Interventional | 2018-06-22 | Active, not recruiting | |||
| Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
| Prospective, Randomized Trial of 3 Rapamycin-Eluting Stents With Different Polymer Coating Strategies For The Reduction of Coronary Restenosis (ISAR-TEST-3)[NCT00350454] | Phase 4 | 605 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Clinical and Angiographic Evaluation of Paclitaxel Eluting, Non-Polymeric, Nanoporous Carbon-Carbon Coated, Cobalt-Chromium Stent[NCT00428662] | 200 participants | Interventional | 2007-01-31 | Recruiting | |||
| A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for lactic acid and Coronary Restenosis
| Article | Year |
|---|---|
Nobori™ drug eluting stent system: clinical evidence update.
Topics: Clinical Trials as Topic; Coronary Restenosis; Drug-Eluting Stents; Equipment Design; Follow-Up Stud | 2010 |
[Research progress of the drug-coated stents].
Topics: Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Restenosis; Drug Delivery | 2005 |
BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.
Topics: Animals; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Carrier | 2006 |
[Molecular mechanism of in-stent restenosis and novel treatment strategy of gene-eluting stent developed with bioabsorbable nanoparticle electrodeposition].
Topics: Absorbable Implants; Animals; Chemokine CCL2; Coronary Restenosis; Electrodes; Gene Transfer Techniq | 2007 |
5 trials available for lactic acid and Coronary Restenosis
| Article | Year |
|---|---|
A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Belgium; Cardiovascular Agents; Coronary Angiography; | 2014 |
The ProLimus trial: a prospective, non-randomised, multicentre trial to evaluate the safety and clinical performance of the pimecrolimus eluting stent system (ProGenic).
Topics: Aged; Angioplasty, Balloon, Coronary; Belgium; Cardiovascular Agents; Chromium Alloys; Coronary Angi | 2009 |
Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Argentina; Cardiovascular Agents; Chi-Square Distribution; Coa | 2011 |
Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries.
Topics: Aged; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary | 2012 |
Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
Topics: Aged; Anticoagulants; Catheterization; Cineangiography; Coated Materials, Biocompatible; Comorbidity | 2004 |
21 other studies available for lactic acid and Coronary Restenosis
| Article | Year |
|---|---|
Electrografting of a biodegradable layer as a primer adhesion coating onto a metallic stent: in vitro and in vivo evaluations.
Topics: Angioplasty; Animals; Arteries; Biocompatible Materials; Cell Adhesion; Coronary Restenosis; Drug De | 2013 |
Advanced cardiovascular stent coated with nanofiber.
Topics: Cell Proliferation; Cells, Cultured; Chemistry, Pharmaceutical; Chitosan; Coronary Restenosis; Drug | 2013 |
Dexamethasone dipropionate loaded nanoparticles of α-elastin-g-PLGA for potential treatment of restenosis.
Topics: Animals; Cattle; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coronary Restenosis; Dex | 2013 |
6-Month Follow-Up of a Novel Biodegradable Drug-Eluting Stent Composed of Poly-L-Lactic Acid and Amorphous Calcium Phosphate Nanoparticles in Porcine Coronary Artery.
Topics: Absorbable Implants; Animals; Calcium Phosphates; Coronary Restenosis; Coronary Vessels; Drug Implan | 2015 |
Nanostructured ultra-thin patches for ultrasound-modulated delivery of anti-restenotic drug.
Topics: Barium Compounds; Cardiovascular Agents; Cell Adhesion; Cells, Cultured; Coronary Restenosis; Drug C | 2016 |
Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis.
Topics: Acetates; Calorimetry, Differential Scanning; Cell Count; Cell Movement; Cell Proliferation; Coated | 2016 |
Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents.
Topics: Absorption; Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Coated Materials, Bioc | 2008 |
[Influence of curcumin--loaded poly (lactide-co-glycolide) films on the proliferation of vascular smooth muscle cells].
Topics: Angioplasty, Balloon, Coronary; Animals; Carotid Arteries; Cell Proliferation; Cells, Cultured; Coat | 2008 |
Production and in vitro characterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries.
Topics: Absorbable Implants; Cardiotonic Agents; Coronary Restenosis; Coronary Vessels; Humans; Lactic Acid; | 2008 |
Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Cations; Cells, | 2009 |
New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles.
Topics: Acrylic Resins; Adhesiveness; Animals; Cell Survival; Coronary Restenosis; Dogs; Drug Carriers; Drug | 2009 |
Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies.
Topics: Animals; Antineoplastic Agents; Aorta, Abdominal; Calcium Phosphates; Coronary Artery Disease; Coron | 2011 |
Nanoburrs seek, heal injury in artery.
Topics: Absorbable Implants; Atherosclerosis; Cardiotonic Agents; Coronary Restenosis; Coronary Vessels; Dru | 2011 |
Microsphere-integrated drug-eluting stents: PLGA microsphere integration in hydrogel coating for local and prolonged delivery of hydrophilic antirestenosis agents.
Topics: Animals; Chemistry, Pharmaceutical; Coronary Restenosis; Dextrans; Drug Delivery Systems; Drug-Eluti | 2011 |
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog | 2012 |
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog | 2012 |
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog | 2012 |
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog | 2012 |
Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis.
Topics: Acrylic Resins; Animals; Cardiac Catheters; Cardiovascular Agents; Chemistry, Pharmaceutical; Corona | 2013 |
A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model.
Topics: Analysis of Variance; Animals; Carbon; Chromium; Coated Materials, Biocompatible; Cobalt; Coronary A | 2006 |
Release of anti-restenosis drugs from poly(ethylene oxide)-poly(DL-lactic-co-glycolic acid) nanoparticles.
Topics: Coronary Restenosis; Dexamethasone; Diffusion; Drug Carriers; Epoxy Compounds; Ethylene Oxide; Lacti | 2006 |
In vitro studies of platelet adhesion, activation, and protein adsorption on curcumin-eluting biodegradable stent materials.
Topics: Adsorption; Biocompatible Materials; Coated Materials, Biocompatible; Coronary Restenosis; Coronary | 2007 |
Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin.
Topics: Absorbable Implants; Adsorption; Angioplasty, Balloon, Coronary; Blood; Coated Materials, Biocompati | 2007 |
[Preparation and anticoagulation of curcumin/poly(lactic acid-co-glycol acid) composite films].
Topics: Coated Materials, Biocompatible; Coronary Restenosis; Curcumin; Drug-Eluting Stents; Humans; Lactic | 2008 |